Skip to Content
Merck

Preparative method of R-(-)-lbuprofen by diastereomer crystallization.

Archives of pharmacal research (2006-02-24)
Tran Quoc Trung, Jong Moon Kim, Kyeong Ho Kim
ABSTRACT

The economic and effective method for preparation of R-(-)-ibuprofen by diastereomer crystallization was developed. R-(-)-ibuprofen was resolved from racemic ibuprofen by forming R-(-)-ibuprofen-R-(+)-alpha-methylbenzylamine diastereomeric salt with R-(+)-alpha(-methylbenzylamine and crystallization. The purity of R-(-)-ibuprofen-R-(+)-alpha-methylbenzylamine diastereomeric salt was tested and confirmed using HPLC and 1H-NMR method. The pure diastereomeric salt collected from repeated recrystallization was further fractionated by liquid-liquid extraction to the pure enantiomer without racemization. R-(-)-ibuprofen was recovered producing overall yield of 2.4% with the purity more than 99.97%.

MATERIALS
Product Number
Brand
Product Description

Supelco
(R)-(+)-α-Methylbenzylamine, for chiral derivatization, LiChropur, ≥99.0%
Sigma-Aldrich
α-Methylbenzylamine, 99%
Sigma-Aldrich
(R)-(+)-α-Methylbenzylamine, ChiPros®, produced by BASF, ≥99.0%
Sigma-Aldrich
(R)-(+)-α-Methylbenzylamine, 98%
Sigma-Aldrich
(R)-(+)-α-Methylbenzylamine, purum, ≥98.0% (sum of enantiomers, GC)
Sigma-Aldrich
(S)-(−)-α-Methylbenzylamine, 98%